| HOME >> BIOLOGY >> TECHNOLOGY |
EDMONTON, Aug. 5 /PRNewswire/ - Exciton Technologies Inc. today announced that the Company has received approval from the United States Food and Drug Administration (FDA) to market exSALT(TM) SD7 Wound Dressing, a product incorporating Exciton's patented platform coating technology utilizing silver oxysalts as the active ingredient.
"This achievement represents a significant team effort and a strong belief in our product," stated Rod Precht, Exciton's President and Chief Executive Officer. "To date, our technologies have demonstrated superior attributes over other leading silver technologies, allowing us to offer effective products at a significantly lower cost. With the approval from the FDA, we can now finalize our commercialization efforts to launch the exSALT(TM) dressing in North America later this year. In addition to preparing for the launch of the exSALT(TM) dressing, the Company is currently in the process of negotiating licensing and distribution agreements with leading wound care companies to broaden our marketing network globally."
The global wound-care market was $14 billion in 2008 and is expected to exceed $17 billion by 2012. Although silver-based products currently comprise a relatively small portion of this market, it is rapidly growing by 25% annually and is expected to grow to $750 million by 2015 due to the natural therapeutic benefits of silver. According to the Centers for Disease Control and Prevention, hospital-acquired infections in the United States alone cost up to $30 billion a year. Exciton's silver-based products have the potential to capitalize an even larger market by:
- Utilizing a more active form of silver;
- Reducing costs; and
- Being amendable to more applications such as consumer products,
catheters and orthopedic devices.
About exSALT(TM)
----------------
Silver has powerful antimicrobial properties. In the proper chemical form, i
'/>"/>
| SOURCE Exciton Technolgies Inc. Copyright©2009 PR Newswire. All rights reserved |